atazanavir + saquinavir + nucleoside analogues

Atazanavir + saquinavir + nucleoside analogues is a combination antiretroviral regimen used in the treatment of HIV-1 infection. Atazanavir and saquinavir are both **protease inhibitors** that block the action of the HIV protease enzyme, preventing viral replication. Nucleoside analogues (commonly nucleoside reverse transcriptase inhibitors, NRTIs) inhibit the reverse transcriptase enzyme, causing premature termination of viral DNA synthesis. This combination targets two critical steps in HIV replication, aiming for effective viral suppression and reduction in the development of resistance. The regimen is primarily used in patients with HIV infection, typically in cases where previous therapies have failed or resistance has developed. Atazanavir may increase saquinavir levels through inhibition of CYP3A4, enhancing the effectiveness of the combination but requiring monitoring for additive side effects.